Evidence map›Paper›PMID 41398666›Full record

ArticleBMC infectious diseases2025

Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients: a comparative study.

Wen Luo, Ke-Yi Li, Wenliang Zhu, Chunmei Dai, Juan Lin, Fang Lu, Qiujuan Chen, Wanyu Wang, Qihong Zhuang, Yihua Lin

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wen Luo *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Ke-Yi Li *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Wenliang Zhu *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Chunmei DaiDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Juan LinDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Fang LuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Qiujuan ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Wanyu WangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Qihong ZhuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China. zhuangqihong1@163.com.
Yihua LinDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China. lyh7@xmu.edu.cn.ORCID https://orcid.org/0000-0002-9354-7704

Funding

Xiamen Medical and Health Guiding Project 3502Z20214ZD1005Xiamen Medical and Health Key Projects 3502Z20234010
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the association between the use of Nirmatrelvir-ritonavir (NMVr) and the risk of intubation or in-hospital mortality among severe COVID-19 patients using real-world data.

methodsA retrospective cohort from the First Affiliated Hospital of Xiamen University, ranging from December 15, 2022 to February 15, 2023, was utilized. To control for confounding factors, multivariable Cox proportional-hazards regression models were applied, adjusted using the inverse probability of treatment weighting (IPTW) based on propensity scores.

resultsA total of 1436 consecutive patients with COVID-19 were included. 265 patients were included in the final analysis, of whom 169 received the treatment of NMVr and 96 did not. The application of NMVr was significantly associated with a reduced risk of the composite endpoint after adjustment (HR, 0.58; 95% CI, 0.35 to 0.97; P = 0.0374). The results were robust to various sensitivity analyses.

conclusionsThe study suggests that NMVr administration is associated with a lower risk of adverse outcomes in severe COVID-19 patients, underscoring the necessity for additional trials to confirm its therapeutic efficacy.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentIntubation, IntratrachealRitonavirAgedDrug CombinationsFemaleHospital MortalityHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesSARS-CoV-2Antiviral AgentsDrug CombinationsRitonavirInverse probability treatment weightingNirmatrelvir-ritonavirReal-worldSevere COVID-19

Identifiers

PMID41398666
PMCPMC12706905

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.